Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica

Initial criteria

• age ≥ 18 years
• EITHER medication used for first-line therapy with liver confined unresectable disease ineligible for transplant OR extrahepatic/metastatic disease ineligible for resection, transplant, or locoregional therapy, OR medication used as subsequent-line therapy
• used in combination with bevacizumab
• prescribed by or in consultation with an oncologist

Approval duration

not stated